News Releases

News Category

Year

26 Oct '2020

Advaxis’ ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial

Disease control rate of 67% in first six evaluable patients who had progressed on KEYTRUDA Approximate 50% improvement in disease control rate versus the rate s reported in other checkpoint rechallenge studies Durable, sustained tumor control of over 43 and 33 weeks observed in first two

PDF Version

15 Oct '2020

Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020

PRINCETON, N.J. , Oct. 15, 2020 (GLOBE NEWSWIRE) -- Advaxis , Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it will present an ePoster at the 35 th Annual Meeting of the Society for Immunology

PDF Version

29 Sep '2020

Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan

PRINCETON, N.J. , Sept. 29, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that its Board of Directors has approved the adoption of a limited duration

PDF Version

24 Sep '2020

Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer

Strategic transition to Investigator sponsored IND from previously announced Advaxis sponsored IND Initiation of investigator sponsored Phase 1 study of ADXS-504 in prostate cancer on-track for Q4 2020 PRINCETON, N.J. , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc.

PDF Version

10 Sep '2020

Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update

Strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and or restore sensitivity to checkpoint inhibitors Enrolling in Phase 1/2 Study efficacy expansion of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two of three evaluable patients

PDF Version

04 Sep '2020

Advaxis Announces Resignation of Chief Financial Officer

PRINCETON, N.J. , Sept. 04, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that Molly Henderson , Executive Vice President and Chief Financial Officer, has

PDF Version

27 Aug '2020

Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference

PRINCETON, N.J. , Aug. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin , President and Chief Executive Officer of Advaxis , will

PDF Version

03 Aug '2020

Advaxis Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital

PRINCETON, N.J. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that it has entered into a common stock purchase agreement for up to $20 million with

PDF Version

23 Jun '2020

Advaxis to be Featured in “Grand Rounds: a Webinar in Biotech and Specialty Pharma,” Hosted by Alliance Global Partners

PRINCETON, N.J. , June 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin , President and Chief Executive Officer of Advaxis , will be

PDF Version

11 Jun '2020

Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update

Expanding Phase 1/2 Study of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two patients from Part B combination arm with KEYTRUDA® Increasing patient enrollment in Part B and initiating Part C to move into first-line regimen with KEYTRUDA® in patients ineligible for

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 21